IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Sujan K Dhar[a], Vishnupriyan K[b], Sharat Damodar[c], Shashi Gujar[d] and Manjula Das[b*]

[a] Beyond Antibody, InCite Lab, MSMF, 8th Floor MSMC, Bommasandra, Bangalore, India

[b] Tumor Immunology, MSMF, 8th Floor MSMC, Bommasandra, Bangalore, India

[c] Department of Hematology,7th Floor MSMC, Bommasandra, Bangalore, India

[d] Room, 11J, 5850 College Street, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5

*Corresponding author:
Dr Manjula Das (manjula.msmf@gmail.com)
Tumour Immunology, Mazumdar Shaw Medical Foundation
8th Floor MSMC, Bommasandra, Bangalore, India
Email: manjula.msmf@gmail.com

Keywords: COVID-19, Meta-Analysis, Cytokines, Logistic Models

Abstract

Aims: SARS-CoV-2, an infectious agent behind the ongoing COVID-19 pandemic, induces high levels of cytokines such as IL-1, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ etc in infected individuals which contribute towards the underlying disease patho-physiology. Nonetheless, exact association and contribution of every cytokine towards COVID-19 pathology remains poorly understood. Delineation of the role of the cytokines during COVID-19 holds the key of efficient patient management in clinics. This study performed a comprehensive meta-analysis to establish association between induced cytokines and COVID-19 disease severity to help in prognosis and clinical care.

Main methods: Scientific literature was searched to identify 13 cytokines (IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, TNF-α and IFN-γ) from 18 clinical studies. Standardized mean difference (SMD) for selected 6 cytokines IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ between severe and non-severe COVID-19 patient groups were summarized using random effects model. A classifier was built using logistic regression model with cytokines having significant SMD as covariates.

Key findings: Out of 13 cytokines, IL-6 and IL-10 showed statistically significant SMD across the studies synthesized. Classifier with mean values of both IL-6 and IL-10 as covariates performed well with accuracy of ~ 92% that was significantly higher than accuracy reported in literature with IL-6 and IL-10 as individual covariates.

Significance: Simple panel proposed by us with only two cytokine markers can be used as predictors for fast diagnosis of patients with higher risk of COVID-19 disease deterioration and thus can be managed well for a favourable prognosis.

Introduction

COVID-19 pandemic caused by SARS-CoV-2 has emerged as a major threat to mankind affecting 18+ million people resulting in over 700,000 deaths (1) worldwide. Exuberant inflammation manifested as elevated levels of cytokines, commonly referred as "cytokine storm" (CS) often leads to critical conditions like ARDS (acute respiratory distress syndrome) and death due to multi-organ failure(2).

Innate immune response is the first step of defence mechanism against viral infection. Pattern recognition receptors in host dendritic cells recognize viral genomic DNA or RNA to initiate production of cytokines and chemokines(3) which in turn recruit immune cells like macrophages, neutrophils and T-cells to the site of infection based on their source and target cells(4). Pro-inflammatory cytokines including type I/II interferons, IL-1, IL-6 and TNF-α play major role in initial response, whereas anti-inflammatory molecules like IL-10 are produced during sustained infection to keep a check on inflammation and maintain immune homeostasis(5). Heightened CS induced acute lung damage leading to fatality(6) is a signature of coronavirus family reported earlier for MERS-CoV and SARS-CoV infections(7,8).

In COVID-19, elevated levels of both pro-inflammatory and anti-inflammatory cytokines are reported in multiple clinical studies (9–11). A recently published extensive meta-analysis summarized elevated levels of IL-2, IL-2R, IL-4, IL-6, IL-8, IL-10, TNF-α and IFN-γ in severe group of patients, whereas no significant increase was found in the levels of IL-1β and IL-17(12). A two-arm meta-analysis study synthesized from individual patient data reported statistically significant odds ratio ($p < 0.05$) to sever disease for only two cytokines - IL-6 and Il-10(13). Some meta-analysis efforts reported difference in IL-6 level between severe and non-severe COVID-19 patients in terms of Standardized Mean Difference (SMD) (14), mean difference (15) or ratio of means (16) values that can potentially be used as cut-off to discriminate between severe and non-severe patients. All these meta-analysis summary results were associated with high level of heterogeneity ($I^2 \sim 98 – 100\%$). Another synthesis over three clinical studies determined the elevated ratio IL-6/IFN-γ in severe patients (17) with substantial heterogeneity ($I^2 = 79\%$).

Clinical studies with COVID-19 patient cohorts explored the role of IL-6 alone (18) or along with other cytokines including IL-10, IL-2, IL-4, TNF-α and IFN-γ as prognosticator

77 for severe disease(19). Meta-analysis studies described before(12,14–16,20,21)
78 concluded elevated levels of cytokines in severe COVID-19 patients but did not attempt
79 to establish their prognostic significance, except the study by Elshazli et al who
80 performed decision tree and ROC curve analysis to assess prognostic potential of multiple
81 laboratory parameters including IL-6(13). However, despite numerous clinical studies
82 and meta-analyses any reliable prognostic method that can predict the progression of a
83 patient to severe form of disease based on on-admission cytokine levels remains elusive.
84 In this study, we attempt to arrive at a prognostic method through meta-analysis of the
85 levels of commonly used 13 cytokine markers between severe and non-severe patient
86 groups by building a classifier using a logistic regression model.

87 # Methods

88 ### *Literature Search*

89 We performed the meta-analysis following PRISMA guidelines(22). Literature search was
90 performed in Pubmed, Google Scholar and in preprint archives such as medRxiv, bioRxiv
91 and SSRN library for articles in English published in year 2020 till 31 May 2020. Search
92 terms included COVID-19-specific terms in title of article ("2019-nCov" OR "nCoV-2019"
93 OR "novel coronavirus" OR "SARS-CoV-2" OR "COVID-19" OR COVID19 OR "novel corona
94 virus") along with terms such as "cytokine level" and combinations of common cytokine
95 names and gene symbols. Search strategy was reviewed by all authors and it was decided
96 to retain non-peer reviewed articles in selection in view of the present emerging
97 situation. Identified articles were screened and shortlisted to clinical studies with
98 inclusion criteria as only clinical studies with laboratory data for at least two cytokines
99 for severe and non-severe COVID-19 patient groups. Exclusion criteria for shortlisting
100 included review articles, opinions and commentaries, studies that include other
101 pathological conditions or complications associated with COVID-19 and studies without
102 mean (SD) or median (IQR) data of cytokines for each group.

103 ### *Data Extraction*

104 Selected articles were reviewed independently by two authors (VK and SKD). Data was
105 extracted from articles using standardized forms and was cross-validated. Cytokine
106 levels reported as median (IQR) was converted to mean (SD) using standard
107 methods(23). One study reported non-severe patient data across two groups(24) which

were combined using recommendations in Cochrane Handbook(25) section 6.5.2.10. Another study represented data in subgroups of IgG levels and Neutrophil-to-Lymphocyte ratio (NLR) (26), for which we retained data from only the IgG-low subgroups as that would be closest to early stage of infections, and combined subgroups of high and low NLR values.

Meta-Analysis and Meta-Regression

To assess the effect of each marker, we used the standardized mean difference (SMD) of measured cytokine level (in pg/mL) between severe and non-severe groups including Hedges' correction for positive bias. All calculations were carried out using the metafor library(27) on R statistical software platform. Meta-regression of SMD of a marker was carried out using mixed-effects model with differences in age and sex (measured as percentage of male patients). Publication bias in the studies was analyzed using Funnel Plot and Egger's regression test. Sensitivity of meta-analysis results was assessed by repeating the analysis with leaving out one study at a time and observing significant changes in heterogeneity and summary effect.

Classifier Development

We built a classifier using logistic regression model for categorization of patient groups in to severe and non-severe categories based on mean values of cytokines in the groups. Classifier performance using individual cytokine values or combination of multiple cytokine values are assessed from the Receiver Operating Characteristics (ROC) curve analysis and the area under the curve (AUC).

Results

Study Details

The search yielded a total of 99 "hits" which were screened to select 18 articles containing cytokine levels of severe and non-severe patients reported from clinical studies (Fig. 1). All 18 selected studies were conducted in China and included 1,242 non-severe and 915 severe COVID-19 patients (Table 1). Out of the 18 studies, 7 were non-peer reviewed studies(24,26,28–32) published online in preprint archives.

136 ***Table 1: Details of selected studies***

Author (year)	Non-severe patients			Severe Patients			Clinical Definitions of Severe Patients	Cytokines Measured
	n	Age	Male %	n	Age	Male %		
Chen, 2020(33)	10	50.3 (10.1)	70.0	11	61.2 (7.3)	90.9	NHC guideline, pulmonary lesion	IL-6, IL-10, TNF-α
Feng, 2020(28)	94	62.9 (13.7)	61.7	20	69.2 (11.1)	65.0	NHC guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
He, 2020(34)	12	42.3 (16.8)	31.1	16	62.3 (16.7)	53.6	NHC guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Lv, 2020(35)	115	54.3 (41.5)	50.4	155	58.7 (47.4)	49.7	Not specified	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Nie, 2020(24)	72	40.3 (19.3)	29.1	25	57.3 (15)	52.0	NHC guideline, pulmonary lesion	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Qin, 2020(36)	166	52.1 (15.4)	48.2	286	57 (13.3)	54.2	NHC guideline	IL-6, IL-10, TNF-α
Shi, 2020(29)	22	49.7 (12)	59.7	21	59 (17.3)	72.4	NHC guideline, pulmonary lesion	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Song, 2020(30)	31	48 (16.5)	51.6	42	55.9 (12.2)	71.4	NHC guideline, pulmonary lesion	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Wan, 2020(37)	102	43.1 (13.1)	53.9	21	61.3 (15.6)	52.4	NHC guideline	IL-4, IL-6, IL-10, TNF-α, INF-γ
Wang, 2020(38)	55	40 (14.1)	45.0	14	69.8 (11.4)	50.0	NHC guideline with SpO_2 < 90%	IL-2, IL-4, IL-6, IL-10, TNF-α
Wei, Su, 2020(39)	131	60.1 (12.4)	45.0	98	69.7 (11.6)	60.0	NHC guideline, pulmonary lesion	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Xu, 2020(40)	80	55.7 (17)	37.5	45	57.7 (15.7)	68.9	NHC guideline	IL-6, IL-10
Zhang, Zhou, 2020(26)	44	53.5 (20.1)	47.7	21	58.3 (13.9)	71.4	Not specified	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Zhang, Wang, 2020(31)	29	44.3 (15.8)	58.6	14	61.7 (9.2)	35.7	NHC guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ

Author (year)	Non-severe patients			Severe Patients			Clinical Definitions of Severe Patients	Cytokines Measured
	n	Age	Male %	n	Age	Male %		
Zhang, Yu, 2020(41)	93	38.2 (12.2)	34.4	18	63.3 (24.9)	77.8	WHO guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Zhao, 2020(32)	53	44.8 (15.9)	43.4	18	63.9 (17.2)	38.9	NHC guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Zheng, 2020(42)	22	46.9 (14.7)	40.9	74	56.8 (13.7)	66.2	NHC guideline	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ
Zhu, 2020(43)	111	50 (15.5)	65.8	16	57.5 (11.7)	56.3	NHC guideline, pulmonary lesion	IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ

NHC guideline: (a) Respiratory distress, RR≥30/min, (b) Oxygen saturation level (SpO_2) ≤ 93% at rest and (c) Arterial blood oxygen partial pressure (PaO_2) /oxygen concentration (FiO_2) ≤300 mm Hg.

Pulmonary lesion: >50% lesion progression within 24-48h in pulmonary imaging

WHO guideline: Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO_2 < 90% on room air

Age in mean (SD)



Figure 1: Workflow for selection of studies

146 In most studies the severe patient group was designated based on National Health
147 Commission of China guidelines(44) that specifies (a) Respiratory distress, RR≥30/min,
148 (b) Oxygen saturation level (SpO_2) ≤ 93% at rest and (c) Arterial blood oxygen partial
149 pressure (PaO_2) /oxygen concentration (FiO_2) ≤300 mm Hg. For some studies, pulmonary
150 lesion progression > 50% within 24-48 hours on imaging was used as additional criteria.
151 One study used WHO guideline(45) that categorizes severe patients as adolescent or
152 adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one
153 of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2
154 < 90% on room air.

155 Weighted mean of age of patients in severe group (59.7y, range 55.9 – 69.8) was higher
156 than the non-severe group (50.2y, range 38.2 – 62.9). Severe group also had larger
157 percentage of male patients (57.8%, range 35.7 – 90.9) than non-severe group (48.4%,
158 range 29.1 – 70.0).

159 Measurement of total 13 cytokines (IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
160 12, IL-17, TNF-α and IFN-γ) were reported in the selected 18 studies. However, 13 studies
161 were considered for further analysis since they reported analysis of five or more studies
162 in at least 1000 patients (Supplementary Table S1). These studies reported levels of only
163 6 cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ).

164 ***Meta-analysis of Cytokine Levels***

165 Meta-analysis for SMD value of each marker using a random-effects model showed
166 moderate and statistically significant elevation in severe patients for two cytokines viz.
167 IL-6 (SMD 0.53, 95% CI: 0.26 - 0.80, $p < 0.001$) (Fig. 2a) and IL-10 (SMD 0.64, 95% CI:
168 0.38 – 0.91, $p < 0.0001$) (Fig. 2b). Level of IFN-γ, the type II interferon, showed a weak
169 elevation in severe group (SMD 0.11, 95% CI: -0,01 – 0.23, $p = 0.078$) with moderate
170 significance. Summary effect size of other markers IL-2 ($p = 0.281$), IL-4 ($p = 0.305$) and
171 TNF-α ($p = 0.258$) were not significant (Table 2).

172



Figure 2: Standardized mean difference of (a) IL-6 and (b) IL-10 between severe and non-severe COVID-19 patients

176 ***Table 2: Meta-analysis result summary of six cytokines***

Cytokine	Random Effect Model SMD (95% CI)	Summary Effect p.value	Heterogeneity (I^2)
IL-2	0.12 (-0.10, 0.35)	0.281	66.9%
IL-4	0.15 (-0.13, 0.42)	0.305	79.2%
IL-6	**0.53 (0.26, 0.80)**	**0.0001**	**72.0%**
IL-10	**0.65 (0.38, 0.91)**	**<0.0001**	**73.0%**
TNF-α	0.10 (-0.08, 0.28)	0.258	50.8%
IFN-γ	0.11 (-0.01, 0.23)	0.078	0%

177

178 ***Meta-Regression with Age and Gender Difference***

179 Summary effects of both IL-6 and IL-10 showed substantial heterogeneity ($I^2 \sim 72$-73%)
180 source of which was explored by carrying out meta-regression of IL-6 and IL-10 using (i)
181 SMD of patient age and (ii) difference in male percentage between severe and non-severe
182 groups as moderators in a mixed-effects model. Results revealed IL-10 levels having a
183 dependence on the age difference (coefficient 0.63, $p = 0.012$), whereas the dependence
184 of IL-6 on age was not significant ($p > 0.05$, Fig. 3). No dependence of IL-6 and IL-10 levels
185 were found on gender expressed as difference of male percentage between the two
186 groups (Supplementary Fig. S1). Above results ascribe some of the observed
187 heterogeneity in IL-6 and IL-10 SMD to difference in average age between severe and
188 non-severe group.



Figure 3: Meta-regression bubble plots of (a) IL-6 and (b) IL-10 SMD with difference in age between severe and non-severe groups

Classifier Performance

Our results indicate that out of the analysed cytokines, levels of only the pro-inflammatory IL-6 and the immuno-suppressive IL-10 are significantly elevated in the severe group of patients, an observation reported in other studies as well(19,46). This prompted us to assess the prognostic potential of these markers by developing a logistic regression model using IL-6 and IL-10 mean values as covariates to classify the patient groups as severe and non-severe across all 18 studies. Model using both IL-6 and IL-10 as covariates showed an overall accuracy of 91.7% and area under the corresponding ROC curve as 0.957 (95% CI: 0.898 – 1), which is higher than the corresponding values using IL-6 (accuracy 77.8%, AUC 0.821) and IL-10 (accuracy 80.6%, AUC 0.878) individually as covariates (Table 3, Fig. 4). Model using both IL-6 and IL-10 showed nearly 100% specificity and 83.3% sensitivity for classification in severe and non-severe categories.

205 ***Table 3: Classifier performance summary using only IL-6, only IL-10 and both IL-6***
206 ***and IL-10 as input variables***

Classifier	Accuracy (%)	Sensitivity (%)	Specificity (%)	AUC (95% CI)
IL-6	77.8	66.7	88.9	0.821 (0.680, 0.962)
IL-10	80.6	61.1	100	0.878 (0.766, 0.990)
Both IL-6 and IL-10	91.7	83.3	100	0.957 (0.898, 1)

207



208

209 ***Figure 4: ROC curve for classifier performance using only IL-6, only-10 and both IL-6***
210 ***and IL-10 as input parameters***

211 ***Publication Bias and Sensitivity***

212 Publication bias towards higher SMD of IL-10 levels reported in smaller-size studies
213 manifested as asymmetry in Funnel plot and Egger's regression test ($p < 0.001$), whereas
214 the corresponding bias was not significant ($p = 0.151$) for IL-6 (Supplementary Fig. S2).
215 Sensitivity analysis of the studies showed a large reduction of heterogeneity in IL-6 (I^2
216 value from 72% to 25%) and a moderate reduction for IL-10 (73% to 55%) by leaving
217 out one particular study from the analysis (Supplementary Fig. S3).

Limitations

Primary limitation of this meta-analysis is that the studies are restricted only to Chinese ethnicity, which was not by design but due to the fact that most initial studies were reported from this geographic region, the site of first spread. Also 7 of the 18 studies were non-peer reviewed publications selected as per search strategy. There was some heterogeneity in clinical criteria for severe disease as shown in Table 1. Also recruitment of patients in the studies were at different stages of disease progression, which might have caused bias in the on-admission measurement of laboratory parameters in cytokines.

Discussion

With the sustained spread of COVID-19 in most societies, a suitable prognostic test that can predict progression of a patient to severe state of disease with reasonable accuracy is need of the hour for efficient management and care. Cytokine storm caused by a dysregulation of immune system through increase in immune cell activation versus suppression of anti-inflammatory response is likely to hold the key in discovery of such prognostic factors.

Elevated levels of IL-6, a pro-inflammatory molecule, is known to down-modulate NK cell activity and are also found to be associated with reduction in granzyme and perforin levels causing impairment of lytic activities(47). In COVID-19 patients exacerbation symptoms such as increased body temperature, elevation in inflammation markers like CRP and serum ferritin and progressed chest computed tomography images were associated with increased IL-6 levels which showed a downturn during recovery(48). This association of IL-6 with pulmonary conditions were reported earlier in patients with pneumonia(49) or severe pneumonitis caused by radiation therapy(50).

IL-10, on the other hand, is an anti-inflammatory cytokine that was found elevated in severe COVID-19 patients(2,33,36). Levels of IL-6, IL-10 and TNF-α were also found to be indicators of T-cell exhaustion in COVID-19 patients(51). IL-10 is a multifunctional cytokine whose primary function is to limit the inflammatory response. However, IL-10 is also known to introduce anergy or non-responsiveness of T-cells in anti-tumour cell response(52) as well as in viral infection(53). Blockade of IL-10 using antibody against

248 IL-10 or its receptor or genetic removal of IL-10 resulted in elimination of infection by
249 virus(53–55) or bacterial pathogen(56).

250 Though the levels of cytokines are increased in severe COVID-19 patients, it's implication
251 in a therapeutic perspective remains unclear. Corticosteroids that can potentially
252 suppress cytokines by inhibiting NF-κB transcription factor have been used on COVID-19
253 patients. However, a meta-analysis across studies involving infection of SARS-CoV, SARS-
254 CoV-2 and MERS-CoV showed increased mortality risk ratio (RR 2.11, 95% CI: 1.13 –
255 3.94) for patients treated with corticosteroids(57). In an unique study, anti-TNF-α
256 antibody drug, infliximab, was administered to a small group (n = 7) of severe COVID-19
257 patients without any pre-existing auto-immune condition(58). Though the patients
258 showed decrease in IL-6 level and increase in lymphocyte count post-administration, the
259 cohort size was not adequate to make any conclusion on the end-point benefits. Few other
260 studies used etanercept(59), adalimumab(60) and infliximab(61) therapy successfully
261 for COVID-19 patients, but with pre-existing auto-immune conditions. On the other hand,
262 there have been several studies targeting IL-6 levels using siltuximab, an IL-6 inhibitor
263 or tocilizumab, an IL-6 receptor inhibitor in severe COVID-19 patients. A recent review
264 (62) on few such studies did not reveal any conclusive benefits due to lack of appropriate
265 control groups in design or inadequate statistical significance. Further, the timing for
266 anti-IL-6 agent administration remains critical since an early administration may
267 negatively affect the innate response, while the late administration may not yield desired
268 benefits. Some of the ongoing clinical results using anti-IL-6 therapy will shed more light
269 in near future.

270 Therapeutic strategy of targeting IL-10 has been a nascent topic for infective diseases.
271 Mice models treated with the immunomodulator compound Ammonium
272 trichloro(dioxyethylene-O-O')tellurate (AS101) that inhibits IL-10 transcription showed
273 an improvement in survival from sepsis-related death(63). Similarly, lymphocytic
274 choriomeningitis virus (LCMV) infected mice when treated with anti-IL-10 antibody
275 exhibited enhanced T-cell responses resulting in increased IFN-γ production and
276 reduction in viral load(53). Blockade of IL-10 signalling using an antibody that targets IL-
277 10 receptor also reduced viral titre and persistence in LCMV-infected mice(54,55).
278 Similar in vivo experiments with SARS-CoV-2 infected animal models will be needed to
279 establish IL-10 as a therapeutic target for severe and critical COVID-19 disease.

Despite the unclarity on therapeutic potential of IL-6 and IL-10, their observed levels of elevation in severe COVID-19 patients have prompted clinical researchers to explore use of them as prognosticators. In an earlier study with pneumonia-affected children, IL-6/IL-10 ratio on admission was found to be an indicator of severe disease with sensitivity and specificity of 76.5% and 83.3% respectively (49). In COVID-19 context, ROC curve analysis on an Italian cohort of 77 patients showed IL-6 as a prognostic factor for combined end-point of progression to severe disease and/or in-hospital mortality with AUC = 0.8(18). However, performance of prognosis for progression to severe disease was poorer with AUC = 0.75. In the recently reported meta-analysis over a large number of studies, classifier performance was found to be higher for neutrophil count (AUC = 0.831), lymphocyte (AUC = 0.867) and D-dimer (AUC = 0.876) than using IL-6 as covariate(AUC = 0.632)(13). Another research with 102 COVID-19 patients used logistic regression to evaluate potential of multiple cytokines to diagnose severe and critical patients. Results revealed best prognostic performance for IL-6 (AUC = 0.83), followed by IL-10 (AUC = 0.73) as individual covariates whereas the model with all cytokines showed marginally better performance (AUC 0.86, sensitivity 80.0%, specificity 75.9%).

Other than these cytokines, D-Dimer, CRP level and NLR are explored as diagnostic or prognostic markers in COVID-19. Though a couple of studies focused only on their diagnostic potential for COVID-19 positivity(64,65), ROC analysis in a study with 84 patients hospitalized with COVID-19 pneumonia(66) showed modest performance of NLR and CRP to predict a 7-day endpoint as AUC values of 0.69 (CRP), 0.76 (NLR) and 0.080 (both). Another study with 93 confirmed patients established a slightly higher performance with AUC values as 0.84(NLR) and 0.71(CRP) to distinguish severe and non-severe patients. Pooled ROC curve analysis in a couple of meta-analysis studies showed modest classifier performance for CRP and D-Dimer with AUC values as 0.84 and 0.69(67) and 0.88 and 0.77(68) respectively to discriminate severe and non-sever patients. Since in all these cases the AUC values are below 0.9, predictive values for NLR, CRP and D-Dimer to diagnose severe patients may remain restricted. A recent proteomics study(69) predicted excellent classification performance (AUC = 0.96) for severe and non-severe COVID-19 patients using 22 serum proteins and 7 metabolites as covariates. However, a proteomics infrastructure is not so common in a clinic, limiting clinical utility of this test.

311 In this context, results of the meta-analysis and classification obtained in this study
312 assumes importance in multiple aspects. Firstly, synthesis of a large number of studies
313 (more than many of the cited meta-analyses) demonstrates a significant difference in
314 values for only two cytokines – IL-6 and IL-10 with counter-acting mechanisms,
315 reaffirming the dysregulation of immune response in progression to a severe state.
316 Secondly, even at the absence of individual patient data, ROC curve analysis with mean
317 values of IL-6 and IL-10 levels manifests a high level of classifier performance (AUC > 0.9)
318 in distinguishing severe from non-severe group patients, which is higher than classifier
319 performance from individual studies(18,19). Our results are likely to be more robust
320 since variations from multiple patient cohorts are included in this synthesis. And lastly,
321 it opens the possibility of further research to establish a validated diagnostic test using
322 these two markers for management of COVID-19 patients. Since we are working with
323 mean values of markers in severe or non-severe patient groups and not individual
324 patient-level values, we have refrained from using IL-6/IL-10 ratio as the classifier as was
325 done in the pneumonia study(49). However, availability of patient data from multiple
326 cohorts of severe and non-severe patients can firmly establish and validate the test with
327 the ratio or any other transform as the basis of classification.

328 Conclusion

329 Our findings, summarized over multiple studies, indicate a possible dysregulation in
330 immune response against COVID-19, characterized by two counter-acting cytokines IL-6
331 and IL-10, shifts the balance between non-severe to severe category of patients, and
332 hence measurement of both markers is necessary to demarcate the boundary.
333 Measurement of serum levels IL-6 and IL-10 are inexpensive and can be performed on
334 admission to clinics or care centres with minimum facilities. Such measurement will be
335 key to identify patients with a greater likelihood of progression to severe disease and
336 thereby to adopt necessary precautionary measures.

337 Further trials with multiple cohorts of COVID-19 patients or assimilation of patient-level
338 data from existing cohorts will be needed to establish and validate the test. Other than
339 the diagnostic potential, option of possible therapeutic strategy targeting either IL-6 or
340 IL-10 or both is likely to emerge through analysis of such data.

341

Declaration of Interest

Authors declare that there are no conflicts of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions

SKD: Conceptualization, Data curation, Formal analysis, Writing - original draft, VK: Data curation, Writing – original draft, SD: Validation, SG: Writing – editing & review, MD: Project administration, Writing – editing & review

Acknowledgement

SKD acknowledges Prof. Joy Kuri, Chair, Department of Electronic Science and Engineering, Indian Institute of Science, Bangalore for providing the computational resources.

Supplementary Material

Enclosed

References

1. Coronavirus Disease (COVID-19) Situation Report - 199. World Health Organization. 2020.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395(10223):497–506.
3. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7(2):131–7.
4. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta - Mol Cell Res. 2014;1843(11):2563–82.
5. Rojas JM, Avia M, Martín V, Sevilla N. IL-10: A multifunctional cytokine in viral infections. J Immunol Res. 2017;2017.

370 6. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of
371 the Cytokine Storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.

372 7. Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of
373 proinflammatory cytokines and suppression of innate antiviral response by the
374 novel Middle East respiratory syndrome coronavirus: Implications for
375 pathogenesis and treatment. J Gen Virol. 2013 Dec;94(PART 12):2679–90.

376 8. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes
377 and consequences of cytokine storm and immunopathology. Semin Immunopathol.
378 2017;39(5):529–39.

379 9. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine
380 Storm; What We Know So Far. Front Immunol. 2020;11(June):1–4.

381 10. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L.
382 SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth
383 Factor Rev. 2020;(May):0–1.

384 11. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics
385 of coronavirus disease 2019 cases in Guangzhou, China. Immunology.
386 2020;160(3):261–8.

387 12. Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. The role of
388 cytokine profile and lymphocyte subsets in the severity of coronavirus disease
389 2019 (COVID-19): A systematic review and meta-analysis. Life Sci.
390 2020;258(July):118167.

391 13. Elshazli R, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin M, et al.
392 Diagnostic and prognostic value of hematological and immunological markers in
393 COVID-19 infection: A meta-analysis of 6320 patients. PLoS One.
394 2020;15(8):e0238160.

395 14. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory
396 markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis.
397 2020;96:467–74.

398 15. Aziz M, Fatima R, Assaly R. Elevated Interleukin-6 and Severe COVID-19: A Meta-
399 Analysis. J Med Virol. 2020;0–1.

400 16. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and
401 Meta-Analysis. medRxiv. 2020 Apr;2020.03.30.20048058.

402 17. Lagunas-Rangel FA, Chávez-Valencia V. High IL-6/IFN-γ ratio could be associated
403 with severe disease in COVID-19 patients. J Med Virol. 2020;

404 18. Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, et al. Interleukin-6
405 as prognosticator in patients with COVID-19. J Infect. 2020;81:452–82.

406 19. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-
407 19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes
408 Infect. 2020;9(1):1123–30.

409 20. Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+,
410 CD8+) counts reflect the severity of infection and predict the clinical outcomes in
411 patients with COVID-19. J Infect. 2020;81:318–56.

412 21. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical
413 and immune biomarker abnormalities associated with severe illness and mortality
414 in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med.
415 2020;58(7):1021–8.

416 22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
417 reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8(5):336–41.

418 23. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation
419 from the sample size , median , range and / or interquartile range. 2014;1–13.

420 24. Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z, Zhang Z. Metabolic disturbances and
421 inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-
422 19): a retrospective study. medRxiv. 2020;2020.03.24.20042283.

423 25. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV (editors), editor.
424 Cochrane Handbook for Systematic Reviews of Interventions version 6.0.
425 Cochrane;

426 26. Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, et al. Immune phenotyping based on
427 neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for
428 patients with COVID-19. medRxiv. 2020;2020.03.12.20035048.

429 27. Viechtbauer W. Conducting meta-analyses in R with the metafor. J Stat Softw.

430 2010;36(3):1–48.

431 28. Feng X, Li P, Ma L, Liang H, Lei J, Li W, et al. Clinical Characteristics and Short-Term
432 Outcomes of Severe Patients with COVID-19 in Wuhan, China. medRxiv.
433 2020;2020.04.24.20078063.

434 29. Shi H, He L, Sun W, Xu J, Wang M, Chen X, et al. Clinical Characteristics and
435 Prognostic Factors of 148 COVID-19 Cases in a Secondary Epidemic Area. SSRN
436 Electron J. 2020;

437 30. Song C-Y, Xu J, He J-Q, Lu Y-Q. COVID-19 early warning score: a multi-parameter
438 screening tool to identify highly suspected patients. medRxiv.
439 2020;2020.03.05.20031906.

440 31. zhang huizheng, wang xiaoying, fu zongqiang, luo ming, zhang zhen, zhang ke,
441 et al. Potential Factors for Prediction of Disease Severity of COVID-19 Patients.
442 medRxiv. 2020;2020.03.20.20039818.

443 32. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal Profiling of Cytokines
444 and Chemokines in COVID-19 Reveals Inhibitory Mediators IL-1Ra and IL-10 Are
445 Associated with Disease Severity While Elevated RANTES Is an Early Predictor of
446 Mild Disease. SSRN Electron J. 2020;

447 33. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. Clinical and immunologic features
448 in severe and moderate forms of Coronavirus Disease 2019. J Clin Invest.
449 2020;27(1095):16–20023903.

450 34. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its
451 correlated immune status in COVID-19 pneumonia. J Clin Virol.
452 2020;127(April):104361.

453 35. Lv Z, Cheng S, Le J, Huang J, Feng L, Zhang B, et al. Clinical characteristics and co-
454 infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a
455 retrospective cohort study. Microbes Infect. 2020;

456 36. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response
457 in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;2019(Xx Xxxx):4–
458 10.

459 37. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte

460 subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-
461 19) infected patients. Br J Haematol. 2020;(April):428–37.

462 38. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with
463 Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;(Xx Xxxx):1–9.

464 39. Wei X, Su J, Yang K, Wei J, Wan H, Cao X, et al. Elevations of serum cancer biomarkers
465 correlate with severity of COVID-19. J Med Virol. 2020;0–2.

466 40. XU B, FAN C yu, WANG A lu, ZOU Y long, YU Y han, HE C, et al. Suppressed T cell-
467 mediated immunity in patients with COVID-19: A clinical retrospective study in
468 Wuhan, China. J Infect. 2020;(xxxx).

469 41. Zhang J, Yu M, Tong S, Liu LY, Tang L V. Predictive factors for disease progression
470 in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin
471 Virol. 2020;127(March):104392.

472 42. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
473 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
474 March 2020: Retrospective cohort study. BMJ. 2020;369(March):1–8.

475 43. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-
476 inflammatory parameters to assess the severity of coronavirus disease 2019. Int J
477 Infect Dis. 2020;95:332–9.

478 44. National Health Commission & State Administration of Traditional Chinese
479 Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia.
480 National Health Commission of the People's Republic of China. 2020.

481 45. World Health Organization. (2020). Clinical management of COVID-19: interim
482 guidance, 27 May 2020. World Health Organization. 2020.

483 46. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host
484 immunity of COVID-19 patients with different severity of illness. 2019;2(7):1–11.

485 47. Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, et al.
486 Inhibition of natural killer cell cytotoxicity by interleukin-6: Implications for the
487 pathogenesis of macrophage activation syndrome. Arthritis Rheumatol.
488 2015;67(11):3037–46.

489 48. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin-6 in

490 monitoring severe case of coronavirus disease 2019. EMBO Mol Med.
491 2020;12(7):e12421.

492 49. de Brito R de CCM, Lucena-Silva N, Torres LC, Luna CF, Correia J de B, da Silva GAP.
493 The balance between the serum levels of IL-6 and IL-10 cytokines discriminates
494 mild and severe acute pneumonia. BMC Pulm Med. 2016;16(1):19–21.

495 50. Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a
496 predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49(3):641–
497 8.

498 51. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional
499 Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front
500 Immunol. 2020;11(May):1–7.

501 52. Moore KW, Malefyt RDW, Robert L, Garra AO. Interleukin-10 and the Interleukin-
502 10 Receptor. Mol Cell Biol. 2001;1(1):683–765.

503 53. Maris CH, Chappell CP, Jacob J. Interleukin-10 plays an early role in generating
504 virus-specific T cell anergy. BMC Immunol. 2007;8:9–12.

505 54. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA.
506 Interleukin-10 determines viral clearance or persistence in vivo. Nat Med.
507 2006;12(11):1301–9.

508 55. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, et al. Resolution
509 of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med.
510 2006;203(11):2461–72.

511 56. Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, Pamer EG. Pathogen-Specific CD8
512 T Cell Responses Are Directly Inhibited by IL-10. J Immunol. 2007;179(7):4520–8.

513 57. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on
514 patients with coronavirus infection: a systematic review and meta-analysis. J Infect.
515 2020;81:13–20.

516 58. Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M. Infliximab
517 against severe COVID-19-induced cytokine storm syndrome with organ failure - A
518 cautionary case series. Vol. 24, Critical Care. BioMed Central; 2020. p. 444.

519 59. Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from

520 COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor
521 etanercept. Annals of the Rheumatic Diseases. BMJ Publishing Group; 2020.

522 60. Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, et al. COVID-19
523 infection in Crohn's disease under treatment with adalimumab. Vol. 69, Gut. BMJ
524 Publishing Group; 2020. p. 1364–5.

525 61. Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S. Infliximab for severe ulcerative
526 colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut. NLM
527 (Medline); 2020.

528 62. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we
529 stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine
530 interventions. Autoimmun Rev. 2020;(April):102567.

531 63. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, et al. Anti-IL-10
532 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from
533 Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention.
534 J Immunol. 2002;169(1):384–92.

535 64. Nalbant A, Kaya T, Varim C, Yaylaci S, Tamer A, Cinemre H. Can the
536 neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus
537 2019 disease (COVID-19)? Rev Assoc Med Bras. 2020;66(6):746–51.

538 65. Yufei Y, Mingli L, Xuejiao L, Xuemei D, Yiming J, Qin Q, et al. Utility of the neutrophil-
539 to-lymphocyte ratio and C-reactive protein level for coronavirus disease 2019
540 (COVID-19). Scand J Clin Lab Invest. 2020;0(0):1–5.

541 66. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio
542 as an independent risk factor for mortality in hospitalized patients with COVID-19.
543 J Infect. 2020 Jul;81(1):e6–12.

544 67. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein,
545 procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-
546 analysis. Ther Adv Respir Dis. 2020;14:1–14.

547 68. Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and
548 prognosis: An updated meta-analysis. Med Clin (Barc). 2020 Aug;155(4):143–51.

549 69. Shen B, Yi X, Sun Y, Liu H, Chen H, Guo T, et al. Article Proteomic and Metabolomic

Characterization of COVID-19 Patient Sera ll Article Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. 2020;59–72.